Frequently Asked Questions

1. What is the purpose of the rebate program?

• The rebate program is designed to provide credits to eligible customers following the WAC price reduction of Spiriva HandiHaler and Atrovent HFA, effective January  2025. It supports our customers during the transition period by offering rebates based on purchases made during a specific period.

2. What products are included?

• The following Spiriva HandiHaler and Atrovent HFA products are included in the rebate program:

Eligible Product	NDC
Spiriva HandiHaler 18mcg x 30	00597-0075-41
Spiriva HandiHaler 18mcg x 90	00597-0075-47
Spiriva HandiHaler 18mcg x 5	00597-0075-75
Atrovent HFA 17mcg/Actuation x 12.9	00597-0087-17

3. Who is eligible for the rebate program?

• Eligibility is determined by the class of trade, as determined by Boehringer Ingelheim. Below is a non-exhaustive list of eligible classes of trade.

Eligible Classes of Trade

Retail Pharmacies Specialty Pharmacies Mail-Order Pharmacies Long Term Care Pharmacies Independent Pharmacies Food Store Pharmacies Mixed Retail/LTC Pharmacies Nursing Home Pharmacies Compounding Pharmacies Closed Door Pharmacies Internet Pharmacies

4. Why are some Classes of trade not eligible?

• Certain classes of trade are eligible for the rebate to mitigate potential impacts to (i) patient access, (ii) reimbursement, and (iii) operational efficiencies as a result of the WAC price reduction. Other classes of trade are not expected to experience the same impacts.

5. What is the timeframe for eligible purchases?

• The eligible purchase period runs from December 15, 2024 to December 28, 2024. Only units purchased during this period will qualify for the rebate.

6. Why is the rebate window between these dates?

• The rebate period is set for the final two weeks before the cost adjustment in order to give customers time to manage their inventory ahead of the price change.

7. How is the rebate amount calculated?

• The credit amount will be calculated as: (Quantity purchased between 12/15/24 and 12/28/24) x (Old purchase price – New purchase price).

8. When will the credits be issued?

• We anticipate issuing credits to eligible customers in March 2025. However, timing may vary depending on factors such as verification of eligibility, calculation of purchases, and additional processing steps.

9. How will I receive my rebate?

• The credits will be administered through your wholesaler. If you qualify, you will receive the rebate in the form of a credit on your account.

10. What actions, if any, must I take to receive my rebate?

• No actions are needed. We, as your wholesaler, will work with Boehringer Ingelheim to calculate and issue credits to eligible customers.

11. Who should I contact if I have further questions?

• Please reach out to your account representative for any specific questions or assistance related to the program.

12. What should I do with my current inventory?

• Please continue to sell through your current inventory and adjust your purchases to manage through your inventory levels.  Please do not return salable units.

13. Why are the WAC prices being reduced?

• The decision to reduce WAC prices reflects our ongoing commitment to making treatments more affordable and accessible for patients.

14. Does this mean there will be reduced WAC prices of products in addition to HandiHaler and Atrovent?

• Currently, we are only focusing on reducing the WAC prices for the Spiriva HandiHaler and Atrovent HFA.

15. Why are other WAC prices not being reduced?

• These pricing decisions are based on market conditions and other factors specific to these products.

We do not speculate about future market conditions.